同濟大學(xué)醫(yī)學(xué)菁英分論壇誠邀天下英才！

同濟大學(xué)

醫(yī)學(xué)菁英分論壇

誠邀天下英才

申報海外優(yōu)青

只等你來！

論壇簡介

同濟大學(xué)醫(yī)學(xué)菁英論壇是在“同濟大學(xué)第十一屆國際青年學(xué)者論壇”框架下舉辦的重要活動，由同濟大學(xué)醫(yī)學(xué)院主辦，多家附屬醫(yī)院參與支持。論壇聚焦但不限于以下領(lǐng)域：腦與脊髓、心血管疾病、癌癥基礎(chǔ)與轉(zhuǎn)化、免疫學(xué)、干細(xì)胞、公共衛(wèi)生、護理學(xué)、藥學(xué)、生物醫(yī)學(xué)工程、智能醫(yī)學(xué)工程、康復(fù)醫(yī)學(xué)工程等議題，凝聚海內(nèi)外生命醫(yī)學(xué)領(lǐng)域的青年才俊，共同探討國際科技前沿話題，開拓學(xué)術(shù)視野，促進交流合作。

學(xué)院簡介

1907年，德國醫(yī)生埃里希·寶隆在上海創(chuàng)辦“德文醫(yī)學(xué)堂”，是同濟大學(xué)的前身，也是同濟醫(yī)學(xué)專業(yè)的開端。20世紀(jì)50年代，在全國高等學(xué)校院系布局調(diào)整中，醫(yī)學(xué)院整體遷出至武漢，但同濟人醫(yī)學(xué)情結(jié)至深，歷經(jīng)百年滄桑后，同濟大學(xué)在新世紀(jì)之初重建醫(yī)學(xué)。2000年4月，同濟大學(xué)與原上海鐵道大學(xué)合并，在原上海鐵道大學(xué)醫(yī)學(xué)院的基礎(chǔ)上恢復(fù)設(shè)立了“同濟大學(xué)醫(yī)學(xué)院”。

經(jīng)過快速發(fā)展，醫(yī)學(xué)學(xué)科的整體水平已躋身全國醫(yī)學(xué)院校前10%。2022年進入教育部直屬優(yōu)質(zhì)醫(yī)學(xué)院校名單（共18所院校入選）。在國際國內(nèi)排名方面，QS（Quacquarelli Symonds）排名12，泰晤士高等教育THE排名11。2022年臨床醫(yī)學(xué)學(xué)科進入 ESI 世界前 1‰，8個醫(yī)學(xué)相關(guān)學(xué)科進入ESI世界前1% （世界前沿學(xué)科）。臨床醫(yī)學(xué)專業(yè)和康復(fù)物理治療專業(yè)被列入國家一流本科專業(yè)建設(shè)點。

平臺簡介

“十四五”期間，新增國家級、省部級科研平臺7個，包括心臟病全國重點實驗室，實現(xiàn)國家重點實驗室零的突破。新增了一批高層次科技創(chuàng)新領(lǐng)軍人才，柔性引進中國科學(xué)院院士1人，新增國際院士3人（劉中民教授當(dāng)選俄羅斯工程院外籍院士，鄭加麟教授當(dāng)選歐洲科學(xué)與藝術(shù)院院士（醫(yī)學(xué)學(xué)部）和歐洲科學(xué)院院士，孫毅教授當(dāng)選俄羅斯工程院外籍院士），新增長江學(xué)者2人、杰青6人、優(yōu)青11人。獲批各類科研項目1524項，科研項目立項總經(jīng)費達(dá)12.585億元。截至2025年6月底，牽頭承擔(dān)國家重點研發(fā)計劃首席項目18項。獲批國家自然科學(xué)基金項目958項，獲資助直接經(jīng)費4.75億元，其中重點重大類項目48項，包括基礎(chǔ)中心項目1項、創(chuàng)新群體2項。作為第一完成單位獲國家、省部級科學(xué)技術(shù)獎8項，包括國家科技進步獎二等獎1項、省部級科技一等獎6項、何梁何利獎1項。發(fā)表頂刊論文Nature 4篇、Cell 4篇、The Lancet 1篇、NEJM 3篇、BMJ 2篇等20分以上高影響力論文242篇。

2020年，學(xué)校在復(fù)興同濟醫(yī)科的道路上做出重大布局，將同濟大學(xué)滬西校區(qū)400余畝土地劃歸醫(yī)學(xué)發(fā)展使用，促進醫(yī)學(xué)院及附屬醫(yī)院在產(chǎn)學(xué)研、醫(yī)教研融合創(chuàng)新發(fā)展。2021年，學(xué)校投入近3億，改造修繕科研實驗室、實驗動物中心及生活體育設(shè)施空間2萬余平方米。2023年醫(yī)學(xué)院整體搬遷至滬西同濟醫(yī)學(xué)園區(qū)，未來滬西將建設(shè)成為在國際上具有較高影響力的醫(yī)學(xué)教育培訓(xùn)的高地，醫(yī)學(xué)科學(xué)創(chuàng)新的高地，醫(yī)工交叉創(chuàng)新高地，區(qū)域融合產(chǎn)學(xué)研轉(zhuǎn)化高地。同時，與市區(qū)兩級政府深入合作，打造“一核、一城、一岸”，即以同濟大學(xué)醫(yī)學(xué)院為輻射源，打造生命健康策源核，成為國內(nèi)一流的環(huán)同濟國家生物醫(yī)藥產(chǎn)業(yè)園區(qū)，并同步帶動建設(shè)TOP智創(chuàng)城、蘇河生命水岸，初步形成超百億級環(huán)同濟醫(yī)學(xué)園區(qū)經(jīng)濟圈。

同濟大學(xué)附屬醫(yī)院

附屬第十人民醫(yī)院、附屬同濟醫(yī)院、附屬東方醫(yī)院、附屬上海市肺科醫(yī)院、附屬第一婦嬰保健院、附屬楊浦醫(yī)院、附屬養(yǎng)志康復(fù)醫(yī)院、附屬皮膚病醫(yī)院、附屬上海市第四人民醫(yī)院、附屬精神衛(wèi)生中心、附屬普陀人民醫(yī)院

同濟大學(xué)醫(yī)學(xué)院網(wǎng)址

https://med.tongji.edu.cn/index.htm

2026年國家自然科學(xué)基金委“優(yōu)秀青年科學(xué)基金項目（海外）”即將正式啟動，我們熱切期盼海內(nèi)外青年學(xué)者參與本論壇，并依托同濟大學(xué)醫(yī)學(xué)院進行2026年海外優(yōu)青項目申報！

1

項目定位

優(yōu)秀青年科學(xué)基金項目（海外）旨在吸引和鼓勵在自然科學(xué)、工程技術(shù)等方面已取得較好成績的海外優(yōu)秀青年學(xué)者（含非華裔外籍人才）回國（來華）工作，自主選擇研究方向開展創(chuàng)新性研究，促進青年科學(xué)技術(shù)人才的快速成長，培養(yǎng)一批有望進入世界科技前沿的優(yōu)秀學(xué)術(shù)骨干，為科技強國建設(shè)貢獻力量。

2

待遇保障

?聘任崗位

評聘長聘教職、博士生導(dǎo)師。

?薪酬待遇

提供具有競爭力的薪酬；另享受教學(xué)津貼、科研績效及高水平成果獎勵。優(yōu)秀對口的醫(yī)科研究人才，可獲得附屬醫(yī)院的附加薪酬。

?個人補貼

享受國家、上海市、大學(xué)及附屬醫(yī)院提供的相應(yīng)生活補助共計400萬元以上。

?科研經(jīng)費

200-600萬（國撥經(jīng)費100-300萬，學(xué)校按照國撥經(jīng)費1:1配套）；優(yōu)秀對口的醫(yī)科研究人才，可支持獲得附屬醫(yī)院的附加科研啟動費，一事一議；科研經(jīng)費最高可達(dá)800萬元。

?辦公設(shè)備

學(xué)院提供必需的辦公、實驗用房，在團隊建設(shè)、重大科研項目申請等方面給予傾斜支持。

?住房保障

提供周轉(zhuǎn)人才公寓，同時協(xié)助申請上海市其他人才公寓住房。

?入學(xué)醫(yī)療

辦理上海市戶口享受人才通道，依托市級人才政策及附屬學(xué)校協(xié)調(diào)解決子女入學(xué)入托，提供附屬醫(yī)院貼心醫(yī)療服務(wù)保障。

?招生

優(yōu)先支持博士生和碩士生招生額度。

?團隊

提供5名學(xué)校資助博士后招收指標(biāo)。

?申報輔導(dǎo)

提供貼心一站式服務(wù)，校院多級精細(xì)化有組織申報輔導(dǎo)，申報全程專業(yè)政策咨詢。

3

報名條件

1.遵守中華人民共和國法律法規(guī)，具有良好的科學(xué)道德，自覺踐行新時代科學(xué)家精神；

2.出生日期在1986年1月1日（含）以后；

3.具有博士學(xué)位；

4.研究方向主要為自然科學(xué)、工程技術(shù)等；

5.在2026年4月15日前，一般應(yīng)在海外高校、科研機構(gòu)、企業(yè)研發(fā)機構(gòu)獲得正式教學(xué)或者科研職位，且具有連續(xù)36個月以上工作經(jīng)歷；在海外取得博士學(xué)位且業(yè)績特別突出的，可適當(dāng)放寬工作年限要求；

6.取得同行專家認(rèn)可的科研或技術(shù)等成果，且具有成為該領(lǐng)域?qū)W術(shù)帶頭人或杰出人才的發(fā)展?jié)摿Γ?/p>

7.申請人尚未全職回國（來華）工作，或者2025年1月1日以后回國（來華）工作。獲資助通知后須辭去海外工作或在海外無工作，全職回國（來華）工作不少于3年。

4

論壇舉辦

舉辦時間：

2025年12月26日-2025年12月28日

舉辦方式：

線上線下同步舉行，歡迎線下參觀交流。

5

報名方式

方式1

掃描二維碼登錄報名入口

https://www.wjx.top/vm/wFWTtuX.aspx#

（可復(fù)制鏈接至瀏覽器）

報名截止時間

2025年12月20日 12:00

方式2

通過郵件直接聯(lián)系各中心聯(lián)絡(luò)人進行報名。

心臟病臨床研究中心

The Clinical Research Center for Cardiovascular Diseases of Tongji University

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)醫(yī)學(xué)院心臟病臨床研究中心（以下簡稱“心臟中心”）聚焦心臟病的源頭機制和瓶頸技術(shù)等重大科學(xué)問題，力爭取得心臟病理論研究的系列突破，研發(fā)出心臟病干預(yù)的創(chuàng)新藥物、創(chuàng)新技術(shù)、創(chuàng)新材料和創(chuàng)新器械，解決心臟病防治領(lǐng)域的難題。心臟中心堅持基礎(chǔ)研究與應(yīng)用研究并重，研究與開發(fā)一體化，理論突破與技術(shù)發(fā)明全鏈條貫通。

心臟中心由中國科學(xué)院院士陳義漢教授領(lǐng)銜，研究團隊為國家基金委“卓越研究群體”、“創(chuàng)新研究群體”和教育部“創(chuàng)新團隊”。擁有心臟病全國重點實驗室、國家學(xué)科創(chuàng)新引智基地、國家臨床重點專科（心血管病）、國家衛(wèi)健委冠心病、心律失常和結(jié)構(gòu)性心臟病介入培訓(xùn)基地和上海市心律失常研究中心等重要基地平臺。心臟中心的發(fā)展愿景是打造全球心臟病學(xué)“理論策源地”和“技術(shù)創(chuàng)新中心”。

The Clinical Research Center for Cardiovascular Diseases of Tongji University (hereinafter referred to as the "Heart Center"), focuses on major scientific questions such as the origins and underlying mechanisms of heart diseases, as well as key bottleneck technologies. It strives to achieve a series of breakthroughs in the theoretical research on heart diseases and to develop innovative drugs, technologies, materials, and devices for cardiac intervention, thereby addressing critical challenges in the prevention and treatment of heart diseases. The Heart Center adheres to the principle of giving equal emphasis to basic and applied research, promotes the integration of research and development, and ensures full-chain connectivity from theoretical breakthroughs to technological inventions.

The Heart Center is led by Professor Yi-Han Chen, an academician of the Chinese Academy of Sciences. The research team has been recognized as an "Outstanding Research Group" and "Innovative Research Group" by the National Natural Science Foundation of China, as well as an "Innovation Team" by the Ministry of Education. The Heart Center hosts several key platforms, including the State Key Laboratory of Cardiovascular Diseases, National Discipline Innovation and Talent Introduction Base, the National Clinical Key Specialty, the National Health Commission Training Bases for Interventional Therapies in Coronary Heart Disease, Arrhythmia, and Structural Heart Disease, and the Shanghai Arrhythmia Research Center. The development vision of the Heart Center is to build a global “source of theoretical innovation” and a “center of technological innovation” in cardiology.

聯(lián)絡(luò)人：金老師

郵箱：jxueling@yeah.net

腦與脊髓臨床研究中心

Clinical Center for Brain and Spinal Cord Research

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)腦與脊髓臨床研究中心成立于2017年12月，是同濟大學(xué)六大臨床研究中心之一，依托同濟大學(xué)醫(yī)學(xué)院及附屬醫(yī)院管理及建設(shè)。現(xiàn)任主任為同濟大學(xué)醫(yī)學(xué)院院長、歐洲科學(xué)院院士鄭加麟教授。

為對接國家腦計劃，提升同濟大學(xué)腦與類腦科學(xué)研究水平，發(fā)揮一流學(xué)科引領(lǐng)作用，中心建立了以重大腦疾病為導(dǎo)向的腦科學(xué)交叉平臺，腦科學(xué)“基礎(chǔ)-臨床-人工智能交叉”研究體系，卓越腦科學(xué)及交叉學(xué)科人才培養(yǎng)體系等。中心利用學(xué)科傳統(tǒng)優(yōu)勢，統(tǒng)籌課程體系，改革人才培養(yǎng)模式，加強醫(yī)工交叉，重視基礎(chǔ)與臨床轉(zhuǎn)化，培養(yǎng)卓越醫(yī)學(xué)與腦科學(xué)復(fù)合拔尖創(chuàng)新人才。積極參與國際腦計劃戰(zhàn)略合作，成立中瑞合作實驗室，邀請國內(nèi)外神經(jīng)領(lǐng)域?qū)＜叶ㄆ趯W(xué)術(shù)交流，打造一流的學(xué)術(shù)高地，以一流管理服務(wù)為一流學(xué)科建設(shè)賦能。

中心研究方向涵蓋腦科學(xué)基礎(chǔ)科研及臨床轉(zhuǎn)化、腦科學(xué)與人工智能交叉、脊髓損傷及修復(fù)、臨床神經(jīng)病學(xué)及疾病早期診斷，麻醉與腦功能等。中心科研機構(gòu)包括教育部腦衰老相關(guān)疾病醫(yī)藥基礎(chǔ)研究創(chuàng)新中心、同濟大學(xué)脊柱脊髓損傷再生修復(fù)教育部重點實驗室、上海市麻醉與腦功能調(diào)控重點實驗室、同濟大學(xué)“腦智同飛”聯(lián)合研究中心、同濟大學(xué)醫(yī)學(xué)院人體解剖與組織胚胎學(xué)系、腦與類腦功能轉(zhuǎn)化研究所及中德腦科學(xué)中心等。

中心建立了同濟大學(xué)腦與脊髓臨床研究中心冠名研究員崗位制度；成立至今，已匯聚包括中國科學(xué)院院士、歐洲科學(xué)院院士、歐洲科學(xué)與藝術(shù)院院士、德國國家科學(xué)院院士、諾貝爾生理學(xué)或醫(yī)學(xué)獎獲得者、國家杰青、長江、國家重點引進人才工程專家及“四青”人才等骨干在內(nèi)的多學(xué)科交叉腦科學(xué)基礎(chǔ)與臨床科研團隊。近五年來，同濟大學(xué)腦科學(xué)團隊已在Nature、Cell等國際著名學(xué)術(shù)期刊發(fā)表論文近30篇；獲得科技部重點研發(fā)計劃10余項，國家重大專項、國家自然科學(xué)基金重點專項、國際合作重大項目近10項，在研國家自然科學(xué)基金項目近70余項；圍繞腦科學(xué)領(lǐng)域多次獲得省部級獎勵。

研究方向涵蓋大腦感知原理和感知障礙致病機制，控制運動行為的環(huán)路機制和運動障礙的發(fā)病機理，腦機接口理論與技術(shù)，腦衰老與神經(jīng)退行性疾病相關(guān)醫(yī)藥創(chuàng)新等。

Clinical Center for Brain and Spinal Cord Research of Tongji University was established in December 2017 and is one of the six major clinical research centers of Tongji University. It is managed by Tongji University School of Medicine. The current director is Professor Zheng Jialin, Dean of Tongji University School of Medicine, academic member of the European Academy of Sciences.

To elevate the research level of neuroscience and brain research of Tongji University, the center has established a cross-disciplinary research platform for major brain diseases, a research innovation system covering basic research, clinical research, and artificial intelligence, and the training system for excellent brain science and interdisciplinary talents. The center takes the advantages of traditional disciplines, constructs high level curriculum system, reforms the training program, strengthens the intersection of medicine and engineering, highlights the transformative medicine, and cultivates innovative talents expertizing in medicine and neuroscience. The center joined and is contributing to the International Brain Initiative, established the Sino-Swiss Laboratory, invites experts in the field of neurology for academic communications, creates a first-class academic atmosphere and services to facilitate the first-class research.

The research direction of the center contains basic neuroscience research and clinical translation, the intersection of neuroscience and artificial intelligence, spinal cord injury and repair, clinical neurology and early diagnosis of diseases, anesthesia and brain function, etc. The center includes multiple institutions, such as, the Medical Basic Research Innovation Center for Brain Aging and Related Diseases of the Ministry of Education, the Key Laboratory of Spinal Cord Injury Regeneration and Repair of Tongji University, the Shanghai Key Laboratory of Anesthesia and Brain Function Regulation, the Tongji University-iFlytek Joint Research Center, the Department of Human Anatomy and Embryology of Tongji University School of Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, and the Sino-German Brain Research Center.

The center has gathered experts from basic and clinical research in neuroscience. In the past five years, the neuroscience team at Tongji University has published about 30 articles in high impact journals such as Nature and Cell. The center has been granted with National Program on Key Basic Research Projects, National Natural Science Foundation of China (General Program; Key Program; Major Program), and National Science Funds for Distinguished Young Scholars. The center received multiple National awards in the field of neuroscience.

聯(lián)絡(luò)人：齊老師

郵箱：shashaqi@tongji.edu.cn

癌癥中心

Cancer Center

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)癌癥中心于2017年5月正式揭牌成立，該中心是同濟大學(xué)“十三五”建設(shè)“雙一流”大學(xué)醫(yī)學(xué)口三個重點建設(shè)項目之一，依托同濟大學(xué)醫(yī)學(xué)院和第十人民醫(yī)院、肺科醫(yī)院等我校各附屬醫(yī)院，整合現(xiàn)有的腫瘤臨床、基礎(chǔ)、轉(zhuǎn)化研究團隊，充分發(fā)揮同濟醫(yī)工結(jié)合優(yōu)勢，力爭建設(shè)成為國內(nèi)集臨床與科研為一體、以臨床為核心的具有特色和影響力的國內(nèi)一流、世界知名的癌癥中心。

癌癥中心致力于腫瘤微環(huán)境基礎(chǔ)與轉(zhuǎn)化研究，包括腫瘤發(fā)生發(fā)展機制和轉(zhuǎn)化，腫瘤代謝和免疫微環(huán)境機制研究及靶向，腫瘤治療新靶點篩選及生物免疫治療臨床轉(zhuǎn)化等。近年來，中心所屬基礎(chǔ)和臨床團隊在JAMA、Cell、Nature、Cancer Cell、Cell Research、Nature Communications、Developmental Cell等國際知名期刊上發(fā)表重要學(xué)術(shù)論文360余篇，10分以上論文100余篇；申請或授權(quán)專利60余項，科研轉(zhuǎn)化成果1600萬余；承擔(dān)國家重點研發(fā)計劃、科技部重大研究計劃、國自然基金、上海市自然科學(xué)基金等課題百余項；并獲得教育部科學(xué)技術(shù)進步一等獎、中華醫(yī)學(xué)科技三等獎、上海市科學(xué)技術(shù)獎科技進步獎一等獎、高校科學(xué)研究成果自然科學(xué)獎一等獎多個科技獎項。

癌癥中心重視人才隊伍建設(shè)，由國家杰青、長江學(xué)者、科技部領(lǐng)軍人才、“萬人計劃”獲得者等優(yōu)秀學(xué)科帶頭人領(lǐng)銜，先后引進和培養(yǎng)出國家杰青、優(yōu)青、青年長江、上海市千人、啟明星人才、新優(yōu)青、揚帆計劃獲得者和超級博士后等，培養(yǎng)的研究生也多次獲得國家獎學(xué)金、優(yōu)秀畢業(yè)生等榮譽；同時積極探索國際合作，與美國紀(jì)念斯隆凱特琳癌癥中心、安德森癌癥中心、法國里昂高師、日本、德國等多所重點高校合作，拿到國家自然科學(xué)基金國際交流合作項目、上海市國際交流合作項目等。

The Cancer Center of Tongji University was officially inaugurated in May2017. This center is one of the key construction projects for the establishment of a "Double First-Class" medical university during the13th Five-Year Plan of Tongji University. It relies on the Tongji University School of Medicine and affiliated hospitals such as the Tenth People’s Hospital and the Pulmonary Hospital to integrate existing teams for clinical, basic, and translational cancer research. The center aims to leverage Tongji’s strengths in the integration of medicine and engineering, striving to become a leading cancer center in China that integrates clinical practice and research, with a focus on clinical care and a distinctive and influential presence recognized worldwide.

The Cancer Center is dedicated to foundational and translational research on the tumor microenvironment, including the mechanisms and translation of tumor development, tumor metabolism, and the immune microenvironment mechanisms as well as targeted therapies. It also focuses on screening new therapeutic targets for tumors and clinical translation of biological immunotherapies. In recent years, the center's basic and clinical teams have published over360 significant academic papers in prestigious international journals such as JAMA, Cell, Nature, Cancer Cell, Cell Research, Nature Communications, and Developmental Cell, including more than100 papers with an Impact Factor above10. Additionally, they have applied for or been granted over60 patents and achieved more than16 million in research translation results. The center has undertaken more than100 projects, including those from the National Key R&D Program, the Ministry of Science and Technology’s major research projects, the National Natural Science Foundation, and the Shanghai Natural Science Fund. It has also received multiple science and technology awards, including the First Prize of Scientific and Technological Progress from the Ministry of Education, the Third Prize of Chinese Medical Science and Technology, the First Prize of the Shanghai Science and Technology Progress Award, and the First Prize of the Natural Science Award for University Research Achievements.

The Cancer Center places great emphasis on talent development, led by outstanding academic leaders such as National Outstanding Young Scholars, Yangtze River Scholars, leading talents from the Ministry of Science and Technology, and recipients of the "Ten Thousand Talents Program." It has successively introduced and trained National Outstanding Young Scholars, Excellent Young Scientists, Young Yangtze River Scholars, Shanghai Thousand Talent Plan experts, Rising Stars, New Excellent Young Scholars, winners of the Sailing Plan, and Super Postdoctoral Fellows. Graduate students trained at the center have also received numerous honors, including National Scholarships and titles of Outstanding Graduates. Simultaneously, the center actively explores international collaborations with notable institutions such as the Memorial Sloan Kettering Cancer Center and the MD Anderson Cancer Center in the United States, as well as with key universities in France, Japan, and Germany. This has resulted in successful applications for international exchange and cooperation projects from the National Natural Science Foundation and the Shanghai International Exchange and Cooperation Project.

聯(lián)絡(luò)人：張老師

郵箱：zhy_yu2022@163.com

干細(xì)胞研究中心

Stem Cell Research Center

滑動查看中英文介紹

Swipe to view Chinese and English introduction

干細(xì)胞研究中心成立于2009年，經(jīng)過十余年的發(fā)展，現(xiàn)已發(fā)展成為一支擁有4名國家級人才團隊和14名PI團隊、160余人組成的集基礎(chǔ)研究、轉(zhuǎn)化研究和臨床研究為一體的全鏈條研究基地。中心聚焦干細(xì)胞與胚胎發(fā)育、干細(xì)胞與模式動物、干細(xì)胞與組織器官再生三大研究方向，并取得系列國際領(lǐng)先研究成果：1）利用微量組學(xué)方法揭示了胚胎發(fā)育和干細(xì)胞靜息與激活機制；2）建立了在體細(xì)胞重編程方法并揭示了細(xì)胞命運轉(zhuǎn)換關(guān)鍵調(diào)控機制；3）利用基因編輯手段建立了非人靈長類大動物疾病模型；4）在細(xì)胞和器官同種異體移植通用型方面建立了具有我國自主知識產(chǎn)權(quán)的技術(shù)手段；5）在國際上率先開展了有關(guān)慢性堵塞性肺病等疾病的細(xì)胞移植臨床研究和移植產(chǎn)品研發(fā)。

干細(xì)胞研究中心圍繞上述方向，持續(xù)打造高水平人才梯隊，希望在神經(jīng)、肺、皮膚與毛囊、骨關(guān)節(jié)、肝臟等干細(xì)胞與再生方向引進中外青年人才，在現(xiàn)有科技部中美干細(xì)胞研究中心和教育部重點實驗室的基礎(chǔ)上，形成學(xué)科高峰。

The Stem Cell Research Center was established in 2009 and has developed over a decade into a comprehensive center with the study of basic, translational, and clinical research of stem cells. It consists of a team of 4 national high-level talents and 14 principal investigators, with a total of over 160 members. The center focuses on three major research directions: stem cells and embryonic development, stem cells and model animals, stem cells and tissue and organ regeneration as well. It has achieved a series of internationally leading research results: 1) Revealed the mechanisms of embryonic development and stem cell quiescence and activation through micro-omics methods; 2) Established in vivo cell reprogramming methods and revealed key regulatory mechanisms of cell fate conversion; 3) Created non-human primate large animal disease models using gene editing techniques; 4) Established the technology with independent intellectual property rights in China for universal allogeneic cell and organ transplantation; 5) Pioneered clinical research and product development for cell transplantation in diseases such as chronic obstructive pulmonary disease.

The Stem Cell Research Center is committed to continuously building a high-level talent echelon around these directions, aiming to attract young talents from both home and abroad in the fields of stem cells and regeneration related to the nervous system, lungs, skin and hair follicles, bone and joints, liver, etc. Based on the existing Ministry of Science and Technology approved China US Research Center for Stem Cell and the Ministry of Education Key Laboratory, we seek to form a peak of academic disciplines.

聯(lián)系人：霍老師

郵箱：huorui2008@tongji.edu.cn

感染與免疫研究中心

Research Center for Infection and Immunity

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)感染與免疫研究中心是同濟大學(xué)六大臨床研究中心之一，由病原體與宿主相互作用教育部重點實驗室、同濟大學(xué)傳染病與疫苗研究所和免疫學(xué)與病原生物學(xué)系組成。聚焦三個主要研究方向：①病原體感染與宿主相互作用的機制研究；②病原體感染促進其他疾病發(fā)生發(fā)展的臨床研究；③病原體感染新型診斷技術(shù)、免疫治療策略和藥物研發(fā)。

研究中心依托同濟大學(xué)醫(yī)學(xué)院并整合附屬第十人民醫(yī)院、附屬肺科醫(yī)院、附屬東方醫(yī)院和附屬皮膚病醫(yī)院優(yōu)勢臨床學(xué)科群。擁有先進的檢測分析設(shè)備和儀器平臺。研究團隊由多位杰出學(xué)者組成，包括教育部長江學(xué)者、國家基金委杰青、國家萬人和國家基金委優(yōu)青，承擔(dān)國家級項目40項，其中國家重大、重點項目14項；并取得了一系列重要原創(chuàng)成果，在國際刊物發(fā)表論文129篇，包括Nature、Nature Immunology、Cell Host & Microbe、Nature Microbiology等影響因子10以上刊物論文17篇。獲得教育部自然科學(xué)獎2項。

The Research Center for Infection and Immunity is one of the six major clinical research centers of Tongji University. It consists of the Key Laboratory of Pathogen-Host Interaction of the Ministry of Education, the Institute for Infectious Diseases and Vaccine Development of Tongji University, and the Department of Immunology and Pathogen Biology. It focuses on three main research directions: ① the mechanism of pathogen infection and host interaction; ②clinical research on how pathogen infections promote the occurrence and development of other diseases; ③ new diagnostic technologies for pathogen infection, immunotherapy strategies, and drug research and development.

The research center relies on the Tongji University School of Medicine and integrates the advantageous clinical disciplines of the Affiliated Tenth People's Hospital, Affiliated Pulmonary Hospital, Affiliated Dongfang Hospital, and Affiliated Dermatology Hospital. It possesses advanced detection and analysis equipment and instrument platforms. The research team is composed of many outstanding scholars, including Changjiang Scholars of the Ministry of Education, The National Science Fund for Distinguished Young Scholars, National Ten Thousand Talents Program scholars, and the National Science Fund for Excellent Young Scholars. They have undertaken 40 national-level projects, including 14 major and key projects, and have achieved a series of important original results, publishing 129 papers in international journals, including 17 papers in journals with an impact factor of over 10, such as Nature, Nature Immunology, Cell Host & Microbe, and Nature Microbiology. They have also received two Natural Science Awards from the Ministry of Education.

聯(lián)絡(luò)人：季老師

郵箱：jizhe@tongji.edu.cn

生物醫(yī)學(xué)工程與納米科學(xué)學(xué)院

Institute of Biomedical Engineering and Nanosciences

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)醫(yī)學(xué)院生物醫(yī)學(xué)工程與納米科學(xué)學(xué)院成立于2008年8月，學(xué)院以培養(yǎng)具有國際視野、原始創(chuàng)新、德才兼?zhèn)涞膭?chuàng)新人才為目標(biāo)，以服務(wù)國家大健康戰(zhàn)略和臨床為導(dǎo)向，聚焦重大疾病的新型靶點開發(fā)、生物材料診療、醫(yī)學(xué)影像診斷及康復(fù)儀器研制，開展全方位生物醫(yī)學(xué)工程與納米科學(xué)前沿交叉研究。

學(xué)院目前擁有生物醫(yī)學(xué)工程一級碩士學(xué)位授予點及生物與醫(yī)藥工程博士學(xué)位授予點，設(shè)置“生物材料與催化醫(yī)學(xué)”、“精準(zhǔn)醫(yī)學(xué)與系統(tǒng)生物學(xué)”、“生物醫(yī)學(xué)影像工程”及“智能康復(fù)與醫(yī)療設(shè)備”四個研究方向，以國家基礎(chǔ)科學(xué)研究中心、脊柱脊髓損傷再生修復(fù)教育部重點實驗室、干細(xì)胞與重大疾病學(xué)科創(chuàng)新引智基地、上海市超聲診療工程技術(shù)研究中心、上海市催化醫(yī)學(xué)前沿科學(xué)研究基地、上海市殘聯(lián)智能康復(fù)輔具與技術(shù)重點實驗室等平臺為抓手大力推動生物醫(yī)學(xué)工程學(xué)科發(fā)展。在2023年泰晤士高等教育中國學(xué)科評級中，同濟大學(xué)生物醫(yī)學(xué)工程評級為A-級。

學(xué)院現(xiàn)有一支28人的多學(xué)科交叉特色的專任教學(xué)科研團隊，其中包含中科院院士1名、國家杰青2名、國家優(yōu)青（含海外）4名，具有副高及以上職稱20人，副高及以上專任教師中具有博士學(xué)位的比例為100%。學(xué)院現(xiàn)任院長為中國科學(xué)院院士、無機化學(xué)家施劍林教授。學(xué)院近年來獲批多項科技部國家重點研發(fā)計劃、科技部重點研發(fā)計劃政府間國際合作重點專項、國自然優(yōu)秀青年基金、國自然面上項目、國自然青年基金、上海市基礎(chǔ)研究特區(qū)計劃、上海市教委科研創(chuàng)新計劃自然科學(xué)重大項目等。在Nature Nanotechnology, Nature Communications, JACS, Science Advances, Advanced Materials等國際高水平學(xué)術(shù)期刊發(fā)表論文200余篇，申請/授權(quán)國家發(fā)明專利60余項，實現(xiàn)10余項科研成果轉(zhuǎn)化，轉(zhuǎn)化金額超千萬，帶來直接/間接經(jīng)濟效益數(shù)千萬元，牽頭建立行業(yè)團體標(biāo)準(zhǔn)2項。

The Institute of Biomedical Engineering and Nanosciences, School of Medicine, Tongji University was established in August 2008. The institute aims to cultivate innovative talents with international vision, innovations, moral integrity, and professional competence. We serve the national health initiative and clinical demands by focusing on the development of novel biomarkers, biomaterials-based therapeutics, medical imaging diagnosis, and rehabilitation instruments for major diseases.

Currently, the institute offers a first-class master's degree program in Biomedical Engineering and a doctoral degree program in Biology and Medicine. The research directions include "Biomaterials and Catalytic Medicine," "Precision Medicine and Systems Biology," "Biomedical Imaging Engineering," and "Intelligent Rehabilitation and Medical Equipment." The institute has excellent research platforms including the National Basic Science Research Center, the Key Laboratory of Spine and Spinal cord Injury Repair and Regeneration (Ministry of Education), the Discipline Innovation Base for Stem Cells and Major Diseases, the Shanghai Engineering Technology Research Center for Ultrasonic Diagnosis and Treatment, the Shanghai Frontier Science Research Center for Catalytic Medicine, and the Key Laboratory of Intelligent Rehabilitation Aids and Technology of the Shanghai Disabled Persons' Federation. In the 2023 Times Higher Education China Subject Ratings, Tongji University's Biomedical Engineering was rated A-.

The institute currently has 28 staff with multidisciplinary backgrounds, including 1 academician of the Chinese Academy of Sciences, 2 National Distinguished Youth Scholars, and 4 National Excellent Youth Scholars. The dean of the institute is Professor Jianlin Shi, an academician of the Chinese Academy of Sciences. In recent years, the institute has been awarded numerous national projects including key research and development plans from the Ministry of Science and Technology, key special projects of government international cooperation, the National Natural Science Foundation of China (NSFC) Excellent Youth Scholars, NSFC General Projects, NSFC Youth Fund, Shanghai Basic Research Special Zone Program, and Scientific Research Innovation Plan for Natural Science Major Projects of Shanghai Municipal. The researchers of the institute have published over 200 papers in high-level international academic journals such as Nature Nanotechnology, Nature Communications, JACS, Science Advances, and Advanced Materials. Over 60 national invention patents have been filed. More than 10 items of scientific findings were commercialized, generating direct and indirect economic benefits worth more than tens of millions of CNY. Two items of industrial standards have been initiated to be established.

聯(lián)絡(luò)人：霍老師

郵箱：mfhuo@tongji.edu.cn

公共衛(wèi)生與全科學(xué)院

Public Health and General Medicine College

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)醫(yī)學(xué)院公共衛(wèi)生與全科學(xué)院致力于培養(yǎng)國家公共衛(wèi)生事業(yè)的棟梁和專業(yè)精英。學(xué)院目前擁有973項目科學(xué)家、國家重點研發(fā)計劃負(fù)責(zé)人、國家基金委杰出青年和海外優(yōu)青、國家級省部級專業(yè)學(xué)會主委等高層次學(xué)科領(lǐng)軍人才，逐步建成流行病學(xué)、臨床醫(yī)學(xué)、計算機科學(xué)、人工智能、生物遺傳學(xué)和生物信息學(xué)等多學(xué)科交叉的研究團隊。學(xué)院致力于以多學(xué)科交叉和健康醫(yī)療大數(shù)據(jù)為特色的覆蓋疾病“發(fā)生-診斷-復(fù)發(fā)-生存-管理”全過程的精準(zhǔn)醫(yī)學(xué)研究。

目前重點研究方向主要聚焦于以下兩個：

（1）健康大數(shù)據(jù)科學(xué)：建設(shè)及管理健康大數(shù)據(jù)平臺，以大數(shù)據(jù)為基礎(chǔ)，循證醫(yī)學(xué)為證據(jù)，人工智能為工具，對神經(jīng)精神障礙疾病、心腦血管、癌癥及其他主要慢性病開展精準(zhǔn)的預(yù)測、預(yù)防、診斷、和治療；

（2）人群遺傳與精準(zhǔn)醫(yī)學(xué)：重大遺傳性出生缺陷疾病的遺傳與分子機制、出生缺陷疾病動物模型與治療策略研究。

Tongji University School of Medicine's Public Health and General Medicine College is dedicated to cultivating the pillars and professional elites of the national public health sector. The college currently boasts high-level disciplinary leaders, including scientists from the 973 Program, heads of national key research and development projects, outstanding young scholars recognized by the National Natural Science Foundation, and chairs of national and provincial professional societies. It is gradually establishing interdisciplinary research teams in epidemiology, clinical medicine, computer science, artificial intelligence, genetics, and bioinformatics. The college focuses on precision medicine research that covers the entire process of disease "occurrence-diagnosis-recurrence-survival-management" characterized by interdisciplinary collaboration and health care big data.

Our current key research directions mainly focus on the following two areas:

(1) Health Big Data Science: Building and managing a health big data platform that utilizes big data as the foundation, evidence-based medicine as the proof, and artificial intelligence as the tool to conduct precise predictions, prevention, diagnosis, and treatment of neuropsychiatric disorders, cardiovascular diseases, cancers, and other major chronic diseases.

(2) Population Genetics and Precision Medicine: Researching the genetic and molecular mechanisms of significant hereditary birth defect diseases, as well as developing animal models and treatment strategies for these birth defects.

聯(lián)絡(luò)人：史老師

郵箱：xiujuansh@tongji.edu.cn

藥學(xué)院

School of Pharmaceutical Sciences

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)醫(yī)學(xué)院藥學(xué)院始于1907年建校之初的醫(yī)學(xué)根基，2011年成為藥學(xué)一級學(xué)科碩士學(xué)位授權(quán)點。藥學(xué)院聚焦藥理學(xué)、藥物化學(xué)、藥劑學(xué)、微生物與生物技術(shù)藥物學(xué)、藥物分析學(xué)五大方向，在抗耐藥真菌藥物、心血管及眼科藥理學(xué)、靶向遞送系統(tǒng)、海洋藥物等領(lǐng)域形成特色優(yōu)勢。藥理學(xué)與毒理學(xué)自2017年起穩(wěn)居ESI全球前1%。

藥學(xué)院擁有國家級領(lǐng)軍人才（杰青、優(yōu)青、海外優(yōu)青）及省部級帶頭人組成的師資團隊，依托教育部心律失常重點實驗室、病原體與宿主互作重點實驗室、上海市結(jié)核病重點實驗室等高水平平臺。近五年主持國家重點研發(fā)計劃、國家自然科學(xué)基金等50余項，發(fā)表SCI論文120余篇，科研資源充沛。

藥學(xué)院實施"卓越人才培養(yǎng)計劃"，以數(shù)智化、綠色化、融合化為引領(lǐng)，培養(yǎng)具備國際視野、創(chuàng)新能力與社會責(zé)任感，能勝任藥物研發(fā)、生產(chǎn)、監(jiān)管及教育的高層次藥學(xué)人才。

The School of Pharmaceutical Sciences at Tongji University School of Medicine originated from the medical foundation established in 1907 and was officially authorized to offer a master’s degree in the primary discipline of pharmacy in 2011. The School specializes in five key areas: pharmacology, medicinal chemistry, pharmaceutics, microbiology and biotechnology pharmaceuticals, and pharmaceutical analysis. It has developed notable expertise in areas such as antifungal drugs targeting resistant strains, cardiovascular and ophthalmic pharmacology, targeted drug delivery systems, and marine-derived pharmaceuticals. Since 2017, its pharmacology and toxicology programs have consistently ranked within the top 1% worldwide according to ESI.

The faculty includes nationally recognized experts, such as Distinguished Young Scholars, Excellent Young Scholars, and Outstanding Overseas Young Scholars, along with leaders at provincial and ministerial levels. The School benefits from prestigious platforms like the Ministry of Education Key Laboratory of Cardiac Arrhythmia, the Key Laboratory of Pathogen-Host Interaction, and the Shanghai Key Laboratory of Tuberculosis. In the past five years, it has led over 50 projects, including those funded by the National Key R&D Program and the National Natural Science Foundation, and has published more than 120 papers indexed by SCI, supported by substantial research resources.

The Institute of Pharmaceutical Sciences runs the "Excellence Talent Training Program," which emphasizes digital intelligence, sustainability, and integration. This program aims to develop high-caliber pharmacy professionals with a global perspective, innovative skills, and a strong sense of social responsibility, preparing them to excel in drug research and development, manufacturing, regulation, and education.

聯(lián)絡(luò)人：張老師

郵箱：zhangjieping@tongji.edu.cn

康復(fù)醫(yī)學(xué)院

School of Rehabilitation Sciences

滑動查看中英文介紹

Swipe to view Chinese and English introduction

同濟大學(xué)醫(yī)學(xué)院康復(fù)醫(yī)學(xué)院前身為 2013 年成立的康復(fù)治療學(xué)系，2024 年升格為康復(fù)醫(yī)學(xué)院（籌）。學(xué)院依托同濟大學(xué)醫(yī)學(xué)院及附屬醫(yī)院建設(shè)，是服務(wù)“健康中國”戰(zhàn)略、推動康復(fù)醫(yī)學(xué)與多學(xué)科交叉融合的創(chuàng)新型學(xué)院，現(xiàn)任院長為同濟大學(xué)附屬養(yǎng)志康復(fù)醫(yī)院院長靳令經(jīng)教授。

學(xué)院聚焦智能康復(fù)、再生康復(fù)、康復(fù)工程等前沿方向，充分融合同濟大學(xué)多學(xué)科優(yōu)勢，構(gòu)建起覆蓋康復(fù)醫(yī)學(xué)、康復(fù)治療科學(xué)、智能康復(fù)工程、聽力語言與認(rèn)知行為科學(xué)、再生康復(fù)醫(yī)學(xué)五個方向的學(xué)科體系，形成“醫(yī)工結(jié)合、科教融合、臨床轉(zhuǎn)化”一體化的高層次人才培養(yǎng)與科研創(chuàng)新高地。其科研平臺實力雄厚，擁有康復(fù)醫(yī)學(xué)國家臨床重點專科、中國康復(fù)醫(yī)學(xué)會康復(fù)醫(yī)學(xué)研究中心、上海市康復(fù)醫(yī)學(xué)重中之重研究中心、同濟大學(xué)智能康復(fù)研究院等學(xué)科平臺。

學(xué)院師資力量強大且成果豐碩，現(xiàn)有交叉學(xué)科團隊專任教師 65 人，其中正高級職稱 42 人，博士生導(dǎo)師 48 人，包含國家“萬人計劃”、長江學(xué)者、國家杰青等國家級人才 17 人。近五年，學(xué)院承擔(dān)國家重點研發(fā)計劃、國自然重點項目等國家級項目 70 余項，發(fā)表高水平 SCI 論文 580 余篇，獲授權(quán)專利近 30 項，多項成果實現(xiàn)臨床轉(zhuǎn)化。在人才培養(yǎng)上，學(xué)院推行“基礎(chǔ)理論 + 臨床實踐 + 工程技術(shù)”三導(dǎo)師制培養(yǎng)模式，康復(fù)物理治療專業(yè)成績亮眼，在軟科、武書連等排行榜中連續(xù)多年獲評全國 A + 等級，2019 年與 2025 年兩次通過世界物理治療聯(lián)盟（WPT）國際認(rèn)證，2022 年入選教育部國家級一流本科專業(yè)建設(shè)點，畢業(yè)生就業(yè)率持續(xù)超過 99%。

此外，學(xué)院積極開展國際合作，與芝加哥康復(fù)醫(yī)院、多倫多大學(xué)、帝國理工學(xué)院等國際一流機構(gòu)共建聯(lián)合實驗室，致力于建設(shè)具有全球影響力的康復(fù)科學(xué)與技術(shù)創(chuàng)新中心，不斷提升自身在國際康復(fù)領(lǐng)域的知名度與影響力。

The School of Rehabilitation Medicine at Tongji University School of Medicine originated from the Department of Rehabilitation Therapy, established in 2013, and was upgraded to the School of Rehabilitation Medicine (Provisional) in 2024. Built upon the foundation of Tongji University School of Medicine and its affiliated hospitals, the School is an innovative institution dedicated to serving the national "Healthy China" strategy and promoting the integration of rehabilitation medicine with multiple disciplines. The current Dean is Professor Jin Lingjing, President of Yangzhi Rehabilitation Hospital Affiliated with Tongji University.

Focusing on cutting-edge fields such as intelligent rehabilitation, regenerative rehabilitation, and rehabilitation engineering, the School fully leverages Tongji University's multidisciplinary strengths to construct an academic system covering five major directions: Rehabilitation Medicine, Rehabilitation Therapy Science, Intelligent Rehabilitation Engineering, Hearing-Speech-Language and Cognitive Behavioral Science, and Regenerative Rehabilitation Medicine. It has established an integrated platform for high-level talent cultivation and scientific research innovation characterized by the "integration of medicine and engineering, fusion of science and education, and clinical translation."

The School boasts robust research platforms, including the National Clinical Key Specialty in Rehabilitation Medicine, the Chinese Rehabilitation Medicine Association Rehabilitation Medicine Research Center, the Shanghai Key Priority Research Center for Rehabilitation Medicine, and the Tongji University Intelligent Rehabilitation Research Institute.

The School possesses a strong faculty with outstanding achievements. It currently has 65 full-time interdisciplinary faculty members, including 42 full professors and 48 doctoral supervisors. Among them are 17 national-level talents, such as recipients of the National "Ten Thousand Talents Program," Cheung Kong Scholars, and National Science Fund for Distinguished Young Scholars. Over the past five years, the School has undertaken more than 70 national-level projects, including National Key R&D Program projects and National Natural Science Foundation of China key projects. It has published over 580 high-impact SCI papers, obtained nearly 30 authorized patents, and successfully translated multiple research findings into clinical applications. In talent cultivation, the School implements a "Three-Mentor System" integrating "basic theory + clinical practice + engineering technology." Its Rehabilitation Physical Therapy program has achieved remarkable results, consistently receiving an A+ grade in national rankings such as those by ShanghaiRanking and Wu Shulian. The program passed the international certification by the World Physiotherapy (WPT) in both 2019 and 2025, and was selected for the National First-Class Undergraduate Major Construction Point by the Ministry of Education in 2022. The employment rate for its graduates has consistently exceeded 99%.

Furthermore, the School actively engages in international collaboration, having established joint laboratories with world-renowned institutions such as the Shirley Ryan AbilityLab (formerly the Rehabilitation Institute of Chicago), the University of Toronto, and Imperial College London. It is committed to building a globally influential center for rehabilitation science and technological innovation, continuously enhancing its reputation and impact in the international rehabilitation field.

聯(lián)絡(luò)人：沈老師

郵箱：zshxia18003@tongji.edu.cn

學(xué)院將組織專家對報名信息進行評估，邀請符合學(xué)院戰(zhàn)略發(fā)展需求的學(xué)者參會，同時根據(jù)受邀者情況推薦申請大學(xué)以下職位：

1

青年百人計劃

(1) 青年百人計劃A崗

?基本條件：

在所從事研究的學(xué)科領(lǐng)域中取得高水平科研成果，有突出的學(xué)術(shù)創(chuàng)新能力和發(fā)展?jié)摿Γ瑢W(xué)術(shù)成果達(dá)到國家級高層次青年人才同等水平。具有博士學(xué)位，年齡一般不超過40周歲。聘期內(nèi)全職在崗工作且與同濟大學(xué)簽訂聘用合同。

?支持政策：

1.聘任為長聘教職；

2.提供具有競爭力的薪酬；

3.為引進的青百受聘學(xué)者提供啟動經(jīng)費和一次性補助；

4.所在學(xué)院提供必需的辦公和科研用房，在團隊建設(shè)、研究生招生、重大科研項目申請等方面給予充分支持；

5.提供良好的醫(yī)療保健服務(wù)。

(2) 青年百人計劃B崗

?基本條件：

在所從事研究的學(xué)科領(lǐng)域取得高水平科研成果，有較強的學(xué)術(shù)創(chuàng)新能力和沖擊國家級高層次青年人才計劃的水平，具備團隊合作精神。具有博士學(xué)位，年齡一般不超過35周歲。聘期內(nèi)全職到崗工作且與同濟大學(xué)簽訂聘用合同。

?支持政策：

1.聘任為特聘研究員；

2.提供具有競爭力的薪酬；

3.為引進的青百受聘學(xué)者提供啟動經(jīng)費和住房補助；

4.所在學(xué)院提供必需的辦公和科研用房，在團隊建設(shè)、研究生招生、重大科研項目申請等方面給予充分支持；

5.提供良好的醫(yī)療保健服務(wù)。

2

長聘教職體系

(1) 長聘教授

?基本條件：

申請人應(yīng)活躍在教學(xué)科研第一線，取得國際同行認(rèn)可的突出學(xué)術(shù)成就，具有很高的國際知名度和影響力，在教學(xué)和研究生培養(yǎng)方面表現(xiàn)優(yōu)秀并取得重要成果，在所在院系的學(xué)科建設(shè)中起到重要作用，達(dá)到世界一流大學(xué)（學(xué)科）終身教授的水平。應(yīng)具有博士學(xué)位，年齡原則上不超過45周歲。

?支持政策：

1.提供具有競爭力的薪酬。

2.所在學(xué)院提供必需的辦公和科研用房，并在團隊建設(shè)、研究生招生、重大科研項目申請等方面給予優(yōu)先支持；

3.提供良好的醫(yī)療保健服務(wù)。

(2) 預(yù)聘副教授

?基本條件：

申請人具備良好的教學(xué)能力，在研究方面已取得具有原創(chuàng)性和重要性的研究成果和良好發(fā)展?jié)摿Γ陬I(lǐng)域內(nèi)有一定的知名度和影響力。應(yīng)具有博士學(xué)位，年齡原則上不超過40周歲。

?支持政策：

1.提供具有競爭力的薪酬。

2.所在學(xué)院提供必需的辦公和科研用房，并在團隊建設(shè)、研究生招生、重大科研項目申請等方面給予支持；

3.提供良好的醫(yī)療保健服務(wù)。

(3) 預(yù)聘助理教授

?基本條件：

申請人具有良好的學(xué)術(shù)能力，較強的創(chuàng)新活力和學(xué)術(shù)發(fā)展?jié)摿Α?yīng)具有博士學(xué)位，原則上要有博士后經(jīng)歷或相應(yīng)的科研工作經(jīng)歷，年齡一般不超過35周歲。

?支持政策：

1.提供具有競爭力的薪酬。

2.所在學(xué)院提供必需的辦公和科研用房，并在研究生招生、重大科研項目申請等方面給予支持；

3.提供良好的醫(yī)療保健服務(wù)。

青年論壇聯(lián)系人：

孟老師

電話：021-51030895

郵箱：1753420@tongji.edu.cn

長聘教職聯(lián)系人：

徐老師

電話：021-51030895

郵箱：xsh91351@tongji.edu.cn

來源：醫(yī)學(xué)院人事人才辦公室

同濟Med-Go全球開源！

2025-11-18

同濟大學(xué)醫(yī)學(xué)生命“十五五”規(guī)劃專題會議舉行

2025-10-20

同醫(yī)

精誠濟世

明道致遠(yuǎn)

微信號｜tongji_med

更多內(nèi)容敬請關(guān)注